Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 17.57%.

  • Puma Biotechnology's EBITDA Margin fell 98400.0% to 17.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.83%, marking a year-over-year increase of 25300.0%. This contributed to the annual value of 13.44% for FY2024, which is 4200.0% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's EBITDA Margin is 17.57%, which was down 98400.0% from 12.66% recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's EBITDA Margin registered a high of 27.41% during Q3 2024, and its lowest value of 31.16% during Q2 2021.
  • For the 5-year period, Puma Biotechnology's EBITDA Margin averaged around 7.13%, with its median value being 8.96% (2023).
  • In the last 5 years, Puma Biotechnology's EBITDA Margin crashed by -412600bps in 2021 and then surged by 514200bps in 2022.
  • Over the past 5 years, Puma Biotechnology's EBITDA Margin (Quarter) stood at 0.91% in 2021, then soared by 1358bps to 11.43% in 2022, then surged by 79bps to 20.5% in 2023, then rose by 10bps to 22.62% in 2024, then dropped by -22bps to 17.57% in 2025.
  • Its last three reported values are 17.57% in Q3 2025, 12.66% for Q2 2025, and 8.66% during Q1 2025.